ASSOCIATION OF GALECTIN-3 WITH FACTORS OF DECOMPENSATION OF CHRONIC HEART FAILURE IN PATIENTS WITH OSTEOARTHRITIS

he negative impact of chronic inflammation on the onset and progression of endothelial dysfunction, blood pressure destabilization and renal function deterioration is widely discussed by modern researchers. One of the topical lines of research is studying the effect of osteoarthritis (OA) on the course of chronic heart failure (CHF). Using modern immunological cytokines in the treatment of such patients can contribute to an earlier diagnosis of the risk of decom-pensation of the cardiovascular pathology.
The aim of the study. To study the possibilities of using galectin-3 in CHF patients with preserved and moderately reduced left ventricular ejection fraction and osteoarthritis in combination with CHF decompensation factors.
Materials and methods. A cross-sectional study of 107 CHF patients was carried out: 60 patients formed the study group with combination of CHF and OA; 47 patients were included in comparison group with CHF and without OA. 
A comparative analysis of clinical, laboratory and instrumental parameters, as well as of the galectin-3 level was car-ried out. The relationship between galectin-3 and CHF decompensation factors in the study group was analyzed, and its diagnostic capabilities were assessed. Statistical processing was carried out using the Statistica 10.0 program (StatSoft Inc., USA). The critical level of statistical significance was p < 0.05.
Results. According to the results of the study, in the study group, a statistically significantly higher level of galectin-3 was revealed compared to the one in patients of the comparison group – 42 ± 2.2 and 20 ± 1.5 ng/ml respectively (p < 0.001), as well as statistically significant associations of galectin-3 with blood pressure levels, dyslipidemia, esti-mated glomerular filtration rate, and atrial natriuretic peptide.
Conclusion. The presence of a statistically significant association of galectin-3 with CHF decompensation factors in patients with osteoarthritis reveals new pathogenetic features of the course of this comorbid pathology. Apparently, it is possible to use galectin-3 as a marker for diagnosing decompensation in this group of patients.

1. Miao Q., Zhang Y.L., Miao Q.F. et al. Sudden Death from Ischemic Heart Disease While Driving: Cardiac Pathology, Clinical Characteristics, and Countermeasures. Med Sci Monit. 2021;27:e929212. https://doi.org/10.12659/MSM.929212

2. Kabalyk M.A., Nevzorova V.A. Cardiovascular diseases and osteoarthritis: general mechanisms of development, prospects for joint prevention and therapy. Cardiovascular therapy and prevention. 2021;20(1):26-60 (In Russian). https://doi.org/10.15829/1728-8800-2021-2660

3. Wallace I.J., Worthington S., Felson D.T. et al. Knee osteoarthritis has doubled in

4. prevalence since the mid-20th century. Proceedings of the National Academy of Sciences. 2017;114 (35):9332-36. https://doi.org/10.1073/pnas.1703856114

5. Albasri A., OʼSullivan J.W., Roberts N.W. et al. A comparison of blood pressure in community pharmacies with ambulatory, home and general practitioner office readings: systematic review and meta-analysis. J Hypertens. 2017;35(10):1919-1928. https://doi.org/10.1097/HJH.0000000000001443

6. Weinmann D., Kenn M., Schmidt S. et al. Galectin-8 induces functional disease markers in human osteoarthritis and cooperates with galectins-1 and -3. Cell Mol Life Sci. 2018;75(22):4187-05. https://doi.org/10.1007/s00018-018-2856-2

7. Hu Y., Yéléhé-Okouma M., Ea H.K. et al. Galectin-3: a key player in arthritis. Joint Bone Spine. 2017;84(1):15‒20. https://doi.org/10.1016/j.jbspin.2016.02.029

8. Andrews A.R., Fernandes A.D., Brownmiller S.E. et al. Share Blocking extracellular galectin-3 in patients with osteoarthritis. Contemp Clin Trials Commun. 2019;17:100500. https://doi.org/10.1016/j.conctc.2019.100500

9. Gehlken C., Suthahar N., Meijers W.C. et al. Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin. 2018;14(1):75‒92. https://doi.org/10.1016/j.hfc.2017.08.009

10. Zhong X., Qian X., Chen G. et al. The role of galectin-3 in heart failure and cardiovascular disease. Clin Exp Pharmacol Physiol. 2019;46(3):197‒203. https://doi.org/10.1111/1440-1681.13048

11. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083 (In Russian). https://doi.org/10.15829/1560-4071-2020-4083

12. Nasonov E.L. Rheumatology. Clinical recommendations. M.:GEOTAR-Media;2017:464 (In Russian).

13. Rebrova O.Y. Statistical analysis of medical data. Application of the STATISTICA application software package. M.:Mediasphere;2002:312 (In Russian).

14. Berenbaum F., Griffin T.M., Liu-Bryan R. Metabolic Regulation of Inflammation in Osteoarthritis. Arthritis Rheum. 2017;69(1):9‒21. https://doi.org/10.1002/art.39842

15. Calay E.S., Hotamisligil G.S. Turning off the inflammatory, but not the metabolic, flames. Nat. Med. 2013;19:265‒67. https://doi.org/10.1038/nm.3114

16. Nurmohamed M.T., Heslinga M., Kitas G.D. Cardiovascular comorbidity in rheumatic disease. Nature Reviews Rheumatology. 2015;11(12):693-704. https://doi.org/10.1038/nrrheum.2015.112